This just in from NxStage…
Emil Paganini, MD, joins NxStage® as Critical Care Medical Advisor
LAWRENCE, MA, February 28, 2008 – NxStage Medical, Inc. (Nasdaq: NXTM), announced today that Emil Paganini, MD, formerly Section Head of Dialysis and Extracorporeal Therapy with the Cleveland Clinic Foundation, has joined the company as Critical Care Medical Advisor. Dr. Paganini will provide physician leadership for corporate, clinical, scientific and educational initiatives to accelerate the company’s efforts to transform renal therapies in the critical care environment with innovative yet simple solutions that benefit patients, caregiver’s and society.
"I am excited that this new role will enable me to continue to work with critical care clinicians, as part of a company that is making significant contributions to our critical care community," said Dr. Paganini. "NxStage is committed to optimizing CRRT’s role in improving patient care and is leading the way with innovative support and education for critical care professionals."
Jeff Burbank, President and CEO, explained, "We are very excited to add Dr. Paganini to our team. This represents a significant step forward in strengthening our scientific, clinical and educational initiatives. I believe that Dr. Paganini’s exceptional track-record as an innovative and dynamic contributor will help us to accelerate our efforts to transform renal therapies in the critical care environment."
Dr. Paganini, MD, FACP, FRCP, was most recently Section Head of Dialysis and Extracorporeal Therapy at the Cleveland Clinic Foundation in Cleveland, Ohio. In addition, Dr. Paganini serves as Chairman of the Ohio Society of Nephrology and Past President of the Health Care Financing Administration Network 9/10. Dr. Paganini is a Coordinating Editor of the International Journal of Artificial Organs and serves on the editorial advisory boards of Seminars in Nephrology, Journal of Nephrology, Journal of Vascular Access, Contemporary Dialysis & Nephrology, and Nephrology News & Issues. He is a member with active participation of:
- the American College of Physicians and serves on the Reimbursement Subcommittee,
- the American Medical Association and serves as RUC Nephrology Representative,
- Renal Physicians Association, and serves as AMA PEAC Advisor,
- NephStrategies Inc. where he serves as President.
He is also a member of the cardio-renal advisory board of the FDA. Dr. Paganini’s work has appeared in numerous peer-reviewed journals including Kidney International, Nephrology, Dialysis and Transplant, Journal of the American Society of Nephrology, American Journal of Kidney Disease and Critical Care Medicine.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the companys website at http://www.nxstage.com/>http://www.nxstage.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, Dr. Paganinis ability to help us accelerate efforts to transform renal therapies in the critical care environment, and other factors that are discussed in NxStages filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.